Savaria Declares Monthly Dividend

LAVAL, Québec, June 21, 2024 (GLOBE NEWSWIRE) -- Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, declared today a dividend of 4.33 cents ($0.0433) per common share, in accordance with its monthly dividend policy, payable on July 5, 2024, to shareholders of record of the Corporation at the close of business on June 28, 2024. This is an eligible dividend within the meaning of the Income Tax Act.

About Savaria Corporation

Savaria Corporation (savaria.com) is a global leader in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts and elevators for home and commercial use. It also manufactures and markets a comprehensive selection of pressure management products for the medical market, medical beds for the long-term care market, as well as an extensive line of medical equipment and solutions for the safe handling of patients, including ceiling lifts and slings. The Corporation operates a sales network of dealers worldwide and direct sales offices in North America, Europe (UK, The Netherlands, Switzerland, Italy, Germany, Poland and Czech Republic), Australia and China. Savaria employs approximately 2,400 people globally and its plants are located across Canada, the United States, Mexico, Europe and China.

Facebook : https://www.facebook.com/savariabettermobility
Instagram :https://www.instagram.com/savariacorp/
LinkedIn: https://ca.linkedin.com/company/savaria 

You May Also Be Interested In

• 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
• Purple Exhibits Builds Amazon's Debut at 2026 ESSENCE Festival
• REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting